ライフサイエンスコーパス: adjuvant radiation therapy

1 ng topical agents, surgery, or definitive or adjuvant radiation therapy.

2 % in stages II and III has led to the use of adjuvant radiation therapy.

3 erall mortality, colostomy rates, and use of adjuvant radiation therapy.

4 m mortality, permanent colostomy, and use of adjuvant radiation therapy.

5 -one patients (25%) were selected to receive adjuvant radiation therapy.

6 temic adjuvant therapy and 35% also received adjuvant radiation therapy.

7 as used as the basis for recommendations for adjuvant radiation therapy.

8 r for subtotally resected EPN_PFA, even with adjuvant radiation therapy.

9 was associated with decreased likelihood of adjuvant radiation therapy after breast conservation.

10 She received adjuvant radiation therapy and initiated letrozole, with

11 ed treatment-naive cohorts (both primary and adjuvant radiation therapy) and those with recurrent dis

12 treatment group: lumpectomy, lumpectomy with adjuvant radiation therapy, and mastectomy.

13 Adjuvant radiation therapy appears detrimental to surviv

14 Adjuvant radiation therapy appears detrimental to surviv

15 Adjuvant radiation therapy (ART) for stage I seminoma ca

16 e patients treated with BCT (lumpectomy with adjuvant radiation therapy) at the Medical College of Vi

17 Adjuvant radiation therapy became the standard of care a

18 ion-sparing resection is appropriate because adjuvant radiation therapy can offset the adverse impact

19 over 1400 patients have examined the role of adjuvant radiation therapy compared with observation fol

20 The increasing utilization of adjuvant radiation therapy, especially for early-stage b

21 pear to have systematic access problems with adjuvant radiation therapy following BCS compared with w

22 Prior studies have demonstrated that adjuvant radiation therapy following mastectomy for brea

23 randomized trials, indications for immediate adjuvant radiation therapy following prostatectomy exist

24 The use of adjuvant radiation therapy following prostatectomy is co

25 recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 dise

26 f using a genomic risk model for deciding on adjuvant radiation therapy for prostate cancer treated w

27 e of randomized studies, the real benefit of adjuvant radiation therapy in MCC is unclear.

28 Adjuvant radiation therapy in the management of early st

29 this study was to better define the role of adjuvant radiation therapy in the management of MCC.

30 Prospective evaluation of adjuvant radiation therapy in this setting is warranted.

31 Surveillance without adjuvant radiation therapy is a reasonable option for wo

32 can provide low local recurrence rates when adjuvant radiation therapy is administered.

33 The use of adjuvant radiation therapy is associated with improved s

34 Adjuvant radiation therapy is not recommended for patien

35 In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routin

36 for nodal disease, estrogen receptor status, adjuvant radiation therapy or chemotherapy, neither DFS

37 The routine use of adjuvant radiation therapy remains a controversial topic

38 To determine the optimal adjuvant radiation therapy (RT) dose following resection

39 Adjuvant radiation therapy (RT) has been shown to improv

40 Adjuvant radiation therapy (RT) has consistently demonst

41 The benefit of adjuvant radiation therapy (RT) in stage I endometrial a

42 kemia Group B (CALGB) C9343 trial found that adjuvant radiation therapy (RT) provided minimal benefit

43 The use of adjuvant radiation therapy (RT) to the primary site in M

44 eated with breast-conserving surgery without adjuvant radiation therapy (RT).

45 omplished by complete surgical resection +/- adjuvant radiation therapy should impact strongly on DSS

46 Adjuvant radiation therapy use decreased over time indep

47 median survival for those patients receiving adjuvant radiation therapy was 63 months compared with 4

48 gher for low-volume surgeons, and the use of adjuvant radiation therapy was significantly lower for l

49 Use of LE versus proctectomy and use of adjuvant radiation therapy were compared over time.